Evaluation of Hormonal Contraceptive Treatments in Obese Women
NCT ID: NCT02398903
Last Updated: 2018-08-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
174 participants
OBSERVATIONAL
2015-03-16
2018-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Contraception and Bariatric Surgery: Evaluation of Contraception and Contraceptive Knowledge of Women Undergoing Bariatric Surgery at the University Hospital of Reims
NCT04219852
Changes in Oral Contraceptive Hormones After Gastric Bypass Surgery
NCT01941134
Ovarian Reserve and Bariatric Surgery
NCT04583150
Bariatric Surgery, Hormones, and Quality of Life
NCT03188640
Effect of Obesity, Diabetes and Bariatric Surgery on Pregnancy Outcomes
NCT05753124
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Contraception is an important issue in women with obesity. There are actually few data answering the questions of the efficacy of oral contraceptive in obese women, as this condition could be a risk factor for failure of hormonal contraception, due to the changes in drug metabolism and a larger volume of distribution in obesity. Bariatric surgery is the most efficient therapeutic for weight loss in severe and morbid obesity. In 2011, more than 31 000 bariatric procedures have been performed in France with sleeve gastrectomy and Roux-en-Y gastric bypass (RYGB) representing the two most frequent procedures. Women represent 80 % of surgical patients and most of them are in childbearing age (mean age of 39 years). Obese women who receive surgical treatment for obesity are advised not to conceive for the following 12 to 18 months, both to ensure optimal weight loss and a stable weight during pregnancy, and also to begin pregnancy with optimal nutritional and vitamin status. There are no data on the changes in oral contraceptives concentrations before and after bariatric surgery, as malabsorption and anatomic digestive modifications following surgery may theoretically affect bioavailability.
Primary Objective :
The difference between Css before bariatric surgery and 6 months after the surgery in obese women regardless of the oral contraceptives used. Three different oral contraceptives are employed (two combined oral contraceptive containing ethinyl E2 and levonorgestrel and a progestin contraceptive desogestrel).
Secondary Objectives :
* To assess if the difference of Css before, 6 months and 12 months after surgery is the same in the 3 groups of oral contraceptives and in the 2 groups of surgery
* To compare the Css of obese women before, 6 months and 12 months after surgery to T0 Css of normal-weight patients for each group of oral contraceptive
* To assess the impact of oral contraceptives on gonadotroph axis, hemostatic variables and estrogen-sensitive protein in obese women before and 6 and 12 months after surgery and in normal-weight women
* Analyze of correlation between body composition, nutritional status and Css in the 3 groups of oral contraceptives and in the 2 groups of bariatric surgery
Secondary End Points:
* Css of oral contraceptive agent 12 months after bariatric surgery
* Css of oral contraceptive agent in normal weight women
* Sequential Body composition by DXA and Impedancemetry before and 6 months and 12 months after surgery.
* Nutritional status in obese women before and after surgery (albumin, prealbuminemia, RBP, transferrin, haemoglobin, lipid (total cholesterol, triglycerides, LDL and HDL)
* Evaluation of gonadotroph axis by hormonal assays: FSH, LH, estradiol, AMH, progesterone, testosterone total, Inhibin B in normal-weight women and obese women before and 6 months and 12 months after surgery
* Evaluation of hemostatic variables (protein S, APC) and SHBG in normal-weight women and obese women before and 6 months and 12 months after surgery
* Number of unexpected pregnancies occurred during the study
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Obese women SG
Obese women operated by sleeve gastrectomy
Blood samples for measurement of drug Css
Blood samples for measurement of drug Css
DXA and impedancemetry
Body composition by DXA and impedancemetry
Normal weight women
Normal weight women
Blood samples for measurement of drug Css
Blood samples for measurement of drug Css
DXA and impedancemetry
Body composition by DXA and impedancemetry
Obese women GBP
Obese women operated by Rougastric bypass
Blood samples for measurement of drug Css
Blood samples for measurement of drug Css
DXA and impedancemetry
Body composition by DXA and impedancemetry
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Blood samples for measurement of drug Css
Blood samples for measurement of drug Css
DXA and impedancemetry
Body composition by DXA and impedancemetry
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Obese women (BMI ≥ 35 kg/m² with obesity related comorbidity or BMI ≥ 40 kg/m²) with an indication of bariatric surgery by RYGB or sleeve gastrectomy under oral contraceptive treatment of interest in our study
* Aged 18 to 45 years if desogestrel or 18 to 35 years if COC
* Signed informed consent
* Affiliated to The French Social Security Health insurance
* Healthy Volunteers
* Normal weight (BMI \< 25 kg/m²)
* Women under oral contraceptive treatment
* Aged 18 to 45 years
* Signed informed consent
* Affiliated to The French Social Security Health insurance
Exclusion Criteria
* Contraindication for an oral contraceptive agent as mentioned in the summary of product characteristics
* Positive pregnancy test
18 Years
45 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assistance Publique - Hôpitaux de Paris
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Anne Bachelot, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Assistance Publique - Hôpitaux de Paris
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hôpital Ambroise Paré
Boulogne-Billancourt, , France
Pitié Salpetriere Hospital
Paris, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
P 130942
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.